VIVIMUSTA Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Vivimusta, and what generic alternatives are available?
Vivimusta is a drug marketed by Azurity and is included in one NDA. There is one patent protecting this drug.
The generic ingredient in VIVIMUSTA is bendamustine hydrochloride. There are twenty-three drug master file entries for this compound. Eleven suppliers are listed for this compound. Additional details are available on the bendamustine hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Vivimusta
A generic version of VIVIMUSTA was approved as bendamustine hydrochloride by ACCORD HLTHCARE on December 7th, 2022.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for VIVIMUSTA?
- What are the global sales for VIVIMUSTA?
- What is Average Wholesale Price for VIVIMUSTA?
Summary for VIVIMUSTA
| US Patents: | 1 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 130 |
| Patent Applications: | 1,933 |
| Drug Prices: | Drug price information for VIVIMUSTA |
| What excipients (inactive ingredients) are in VIVIMUSTA? | VIVIMUSTA excipients list |
| DailyMed Link: | VIVIMUSTA at DailyMed |
Pharmacology for VIVIMUSTA
| Drug Class | Alkylating Drug |
| Mechanism of Action | Alkylating Activity |
US Patents and Regulatory Information for VIVIMUSTA
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Azurity | VIVIMUSTA | bendamustine hydrochloride | SOLUTION;INTRAVENOUS | 212209-001 | Dec 7, 2022 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
